Evidence map›Paper›PMID 26063213›Full record

ReviewDrugs2015

Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting.

Gillian M Keating

7 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 229 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
229citing papers in PubMed, 14 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03624595 nacompletednot on this mapstarted 2019, after this paper: background citation

Effect of Low-dose Dexmedetomidine on Postoperative Delirium in Patients After Cardiac Surgery: A Multicenter, Double-blinded, Randomized Controlled Trial

TypeinterventionalSponsorDong-Xin WangRan2019 to 2025Enrolled504ConditionsCardiac Surgery, Cardiopulmonary Bypass, Dexmedetomidine, DeliriumArmsDexmedetomidine, Placebo
NCT04912518 narecruitingnot on this mapstarted 2021, after this paper: background citation

Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial

TypeinterventionalSponsorHarbin Medical UniversityRan2021 to 2025Enrolled250ConditionsST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, CardioprotectionArmsDexmedetomidine (DEX), Placebo (Saline)
NCT05674253 early_phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New Onset Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2023Enrolled248ConditionsAtrial Fibrillation New OnsetArmsDexmedetomidine + Hydrocortisone
NCT05950646 phase4completednot on this mapstarted 2024, after this paper: background citation

Effect of Mini-dose Dexmedetomidine-Esketamine Infusion on Sleep Quality in Older Patients Undergoing Knee or Hip Replacement Surgery: A Multicenter Randomized Controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2024 to 2026Enrolled154ConditionsOld Age, Knee Replacement Surgery, Hip Replacement Surgery, DexmedetomidineArmsDexmedetomidine, Esketamine, Normal saline
NCT06613243 phase4completednot on this mapstarted 2024, after this paper: background citation

Different Doses of Dexmedetomidine Combined With Esketamine for Analgesia in Women Undergoing Cesarean Delivery: a Pilot Randomized Trial

TypeinterventionalSponsorPeking University First HospitalRan2024 to 2024Enrolled120ConditionsCesarean Delivery, Esketamine, Neuropsychiatric Symptoms, DexmedetomidineArmsEsketamine 0.2 mg/kg, Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg, Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg, Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg
NCT07501728 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Intranasal Dexmedetomidine for Prevention of Postpartum Depression in Women Receiving Combined Spinal-Epidural Labor Analgesia: A Randomized Controlled Trial

TypeinterventionalSponsorChengdu Jinjiang Maternity and Child Health HospitalRan2026 to 2027Enrolled270ConditionsPostpartum Depression (PPD)ArmsDexmedetomidine, Placebo
NCT07639099 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Impact of Intranasal Esketamine-dexmedetomidine Combination on Postpartum Depression in Parturients With Prenatal Depressive Symptoms: a Randomized, Double-blind, and Placebo-controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2026 to 2029Enrolled164ConditionsParturients, Depressive Symptoms, Esketamine, DexmedetomidineArmsEsketamine-dexmedetomidine combination, Placebo
3 · Its place in the literature

Who cites it

229 citing papers in PubMed, 14 syntheses or guidelines pooled it, 423 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gillian M KeatingSpringer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand, demail@springer.com.
Springer Nature (New Zealand) · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dexmedetomidine (Dexdor(®)) is a highly selective α2-adrenoceptor agonist. It has sedative, analgesic and opioid-sparing effects and is suitable for short- and longer-term sedation in an intensive care setting. In the randomized, double-blind, multicentre MIDEX and PRODEX trials, longer-term sedation with dexmedetomidine was noninferior to midazolam and propofol in terms of time spent at the target sedation range, as well as being associated with a shorter time to extubation than midazolam or propofol, and a shorter duration of mechanical ventilation than midazolam. Patients receiving dexmedetomidine were also easier to rouse, more co-operative and better able to communicate than patients receiving midazolam or propofol. Dexmedetomidine had beneficial effects on delirium in some randomized, controlled trials (e.g. patients receiving dexmedetomidine were less likely to experience delirium than patients receiving midazolam, propofol or remifentanil and had more delirium- and coma-free days than patients receiving lorazepam). Intravenous dexmedetomidine had an acceptable tolerability profile; hypotension, hypertension and bradycardia were the most commonly reported adverse reactions. In conclusion, dexmedetomidine is an important option for sedation in the intensive care setting.

Indexed as

ClonidineCritical CareDeliriumDexmedetomidineDrug InteractionsHumansHypnotics and SedativesProcedural SedationPropofolClonidineDexmedetomidineHypnotics and SedativesPropofol

Identifiers

PMID26063213
OpenAlexW630657035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.